| Document Date: 2012-06-27 14:59:45
Open Document File Size: 539,30 KBShare Result on Facebook
City London / Cambridge / / Company Momenta Pharmaceuticals Inc / 10HPF 0 Sa / / Country United Kingdom / / Facility Cambridge Research Institute / Tuveson laboratory / / IndustryTerm treatment of human pancreatic cancer / / MedicalCondition tumor / Pancreatic Cancer Martijn P. Lolkema1 / human pancreatic cancer / M402-treated tumors / strain / D52 tumors / metastasis / KRAS mutant tumors / several pre-clinical tumor / Reduce Metastasis / pancreatic cancer / less metastases / / Organization Cambridge Research Institute / London School of Medicine / / Person Takashi Kei / Ganlin Zhao / Sucharita Roy / Birgit Schultes / Tanmoy Ganguly / Rain Kwan / Erick Moy / / Position representative / model for pancreatic cancer / / Technology alpha / recombination / /
SocialTag |
Abstract: LB-43 M402, a Novel Heparan Sulfate Mimetic, Synergizes with Gemcitabine to Improve Survival and Reduce Metastasis and Epithelial-to-Mesenchymal Transition (EMT) in a Genetically Engineered Mouse Model for Pan